Evidence map›Paper›PMID 38345635›Full record

ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2024

Challenges and opportunities in inflammatory bowel disease: from current therapeutic strategies to organoid-based models.

Lingjie Kong, Siyan Chen, Shenghao Huang, Anzhe Zheng, Sheng Gao, Jianzhong Ye, Chunyan Hua

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lingjie Kong *School of the 2nd Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Siyan Chen *School of Ophthalmology & Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Shenghao Huang *School of the 2nd Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Anzhe Zheng *School of the 2nd Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Sheng GaoLaboratory Animal Center, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. 4869335@qq.com.
Jianzhong YeDepartment of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. jzye89@163.com.
Chunyan HuaSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. huachunyan@wmu.edu.cn.

Funding

Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province 2022E10022National Natural Science Foundation of China 81901660Natural Science Foundation of Zhejiang Province LTGY23H100001Science and Technology Plan Project of Wenzhou Municipality Y20220045Science and Technology Plan Project of Wenzhou Municipality,China Y20220389
6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) is an increasingly prevalent global health concern that has garnered substantial attention. However, the underlying mechanisms are still unclear and the current treatments have significant limitations. Intestinal organoids provide an in vitro model to explore the pathogenesis, test the therapeutic effects, and develop regenerative treatments as well as offer the potential to transform drug discovery of IBD.

methodsTo advance our understanding of the whole story of IBD spanning from the pathogenesis to the current therapeutic strategies and latest advancements, a comprehensive search of major databases including PubMed, Scopus, and Web of Science was conducted to retrieve original articles and reviews related to IBD, organoids, pathogenesis and therapy.

resultsThis review deciphers the etiopathogenesis and the current therapeutic approaches in the treatment of IBD. Notably, critical aspects of intestinal organoids in IBD, such as their potential applications, viability, cell renewal ability, and barrier functionality are highlighted. We also discuss the advances, limitations, and prospects of intestinal organoids for precision medicine.

conclusionThe latest strides made in research about intestinal organoids help elucidate intricate aspects of IBD pathogenesis, and pave the prospective avenues for novel therapeutic interventions.

Indexed as

Inflammatory Bowel DiseasesOrganoidsAnimalsHumansIntestinesModels, BiologicalEtiopathogenesisInflammatory bowel diseaseOrganoidTherapy

Identifiers

PMID38345635

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.